交易 Agenus - AGEN CFD
加入收藏夹- 概括
- 曆史數據
- 活動
- 收入報表
- 資産負債表
- 現金流
价差 | 0.0068 | ||||||||
多头隔夜费
多头隔夜费
前往平台 | -0.026179% | ||||||||
空头隔夜费
空头隔夜费
前往平台 | 0.003957% | ||||||||
隔夜费时间 | 21:00 (UTC) | ||||||||
最小交易量 | 1 | ||||||||
货币 | USD | ||||||||
保证金 | 5% | ||||||||
上市交易所 | United States of America | ||||||||
交易费 | 0% |
*Information provided by Capital.com
Agenus Inc ESG Risk Ratings
“C”分數表示在公開報告重大 ESG 數據方面令人滿意的相對 ESG 表現和適度的透明度。
- 上週
- 上個月
- 去年
- 過去兩年
- 最大
- 每日
- 每週
- 每月
日期 | 關閉 | 更改 | 變化 (%) | 打開 | 高 | 低 |
---|---|---|---|---|---|---|
Mar 28, 2024 | 0.5689 | 0.0158 | 2.86% | 0.5531 | 0.5690 | 0.5467 |
Mar 27, 2024 | 0.5510 | 0.0078 | 1.44% | 0.5432 | 0.5568 | 0.5317 |
Mar 26, 2024 | 0.5331 | -0.0336 | -5.93% | 0.5667 | 0.5670 | 0.5294 |
Mar 25, 2024 | 0.5537 | 0.0120 | 2.22% | 0.5417 | 0.5540 | 0.5287 |
Mar 22, 2024 | 0.5398 | -0.0267 | -4.71% | 0.5665 | 0.5667 | 0.5167 |
Mar 21, 2024 | 0.5567 | 0.0098 | 1.79% | 0.5469 | 0.5740 | 0.5390 |
Mar 20, 2024 | 0.5477 | -0.0145 | -2.58% | 0.5622 | 0.5622 | 0.5267 |
Mar 19, 2024 | 0.5594 | 0.0285 | 5.37% | 0.5309 | 0.5624 | 0.5199 |
Mar 18, 2024 | 0.5263 | -0.0304 | -5.46% | 0.5567 | 0.5567 | 0.4794 |
Mar 15, 2024 | 0.5366 | -0.0651 | -10.82% | 0.6017 | 0.6017 | 0.5366 |
Mar 14, 2024 | 0.5960 | -0.0627 | -9.52% | 0.6587 | 0.6587 | 0.5867 |
Mar 13, 2024 | 0.6557 | -0.0010 | -0.15% | 0.6567 | 0.7007 | 0.6428 |
Mar 12, 2024 | 0.6640 | -0.0049 | -0.73% | 0.6689 | 0.6878 | 0.6417 |
Mar 11, 2024 | 0.6701 | 0.0038 | 0.57% | 0.6663 | 0.6796 | 0.6417 |
Mar 8, 2024 | 0.6659 | -0.0409 | -5.79% | 0.7068 | 0.7237 | 0.6589 |
Mar 7, 2024 | 0.6949 | -0.0118 | -1.67% | 0.7067 | 0.7127 | 0.6801 |
Mar 6, 2024 | 0.6988 | 0.0299 | 4.47% | 0.6689 | 0.7234 | 0.6667 |
Mar 5, 2024 | 0.6702 | -0.0175 | -2.54% | 0.6877 | 0.7218 | 0.6612 |
Mar 4, 2024 | 0.6869 | 0.0252 | 3.81% | 0.6617 | 0.7367 | 0.6267 |
Mar 1, 2024 | 0.6566 | -0.0184 | -2.73% | 0.6750 | 0.6866 | 0.6566 |
Agenus Events
时间(协调世界时) (UTC) | 国家 | 事件 |
---|---|---|
Wednesday, April 3, 2024 | ||
时间(协调世界时) (UTC) 14:00 | 国家 US
| 事件 Agenus Inc Annual Shareholders Meeting Agenus Inc Annual Shareholders MeetingForecast(预报) -上一页 - |
Tuesday, May 7, 2024 | ||
时间(协调世界时) (UTC) 12:30 | 国家 US
| 事件 Q1 2024 Agenus Inc Earnings Release Q1 2024 Agenus Inc Earnings ReleaseForecast(预报) -上一页 - |
Tuesday, June 11, 2024 | ||
时间(协调世界时) (UTC) 14:30 | 国家 US
| 事件 Agenus Inc Annual Shareholders Meeting Agenus Inc Annual Shareholders MeetingForecast(预报) -上一页 - |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
總收入 | 98.024 | 295.665 | 88.17 | 150.048 | 36.7836 |
收入 | 98.024 | 295.665 | 88.17 | 150.048 | 36.7836 |
總營業費用 | 279.388 | 263.721 | 208.125 | 220.185 | 171.372 |
銷售/一般/行政費用,總計 | 81.007 | 76.359 | 59.218 | 46.041 | 37.3397 |
研究與開發 | 186.691 | 178.608 | 142.617 | 168.339 | 124.6 |
Other Operating Expenses, Total | 5.805 | -1.335 | |||
營業收入 | -181.364 | 31.944 | -119.955 | -70.137 | -134.588 |
利息收入(費用),非經營淨值 | -61.863 | -65.719 | -61.078 | -41.451 | -25.2726 |
其他,淨值 | 12.571 | 5.051 | -1.858 | 0.028 | -2.18328 |
稅前淨收入 | -230.656 | -28.724 | -182.891 | -111.56 | -162.044 |
稅後淨收入 | -230.656 | -28.724 | -182.891 | -111.56 | -162.044 |
未計算非常項目前的淨收益 | -220.074 | -23.926 | -180.914 | -107.657 | -159.692 |
淨收入 | -220.074 | -23.926 | -180.914 | -107.657 | -159.692 |
Total Adjustments to Net Income | -0.212 | -0.211 | -0.209 | -0.208 | -0.20684 |
普通股股東可獲收益 (不含非經常性項目) | -220.286 | -24.137 | -181.123 | -107.865 | -159.899 |
普通股股東可獲收益 (含非經常性項目) | -220.286 | -24.137 | -181.123 | -107.865 | -159.899 |
攤薄淨收入 | -220.286 | -24.137 | -181.123 | -107.865 | -159.899 |
攤薄後加權平均股 | 281.743 | 228.919 | 172.504 | 134.982 | 110.772 |
扣除特別項目的每股攤薄盈利 | -0.78187 | -0.10544 | -1.04996 | -0.79911 | -1.44349 |
Dividends per Share - Common Stock Primary Issue | |||||
每股正常攤薄盈利 | -0.77499 | -0.13251 | -1.0342 | -0.79911 | -1.3463 |
非常規項目總計 | 0 | ||||
異常費用(收入) | 1.937 | -6.197 | 2.72 | 0 | 10.7666 |
少數股東權益 | 10.582 | 4.798 | 1.977 | 3.903 | 2.3519 |
收入成本,共計 | 10.568 | 3.47 | 2.349 | ||
毛利 | 87.456 | 292.195 | 85.821 | ||
利息費用(收入) - 淨運營 | -0.815 | 11.481 | 1.221 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
總收入 | 25.296 | 22.902 | 28.386 | 22.772 | 20.926 |
收入 | 25.296 | 22.902 | 28.386 | 22.772 | 20.926 |
收入成本,共計 | 0.254 | 2.294 | 7.693 | 0.308 | 2.024 |
毛利 | 25.042 | 20.608 | 20.693 | 22.464 | 18.902 |
總營業費用 | 79.962 | 77.243 | 88.08 | 64.417 | 65.491 |
銷售/一般/行政費用,總計 | 20.415 | 18.237 | 25.036 | 18.105 | 18.914 |
研究與開發 | 59.285 | 57.118 | 53.279 | 46.011 | 44.96 |
利息費用(收入) - 淨運營 | 0.008 | -0.406 | 0.135 | -0.007 | -0.407 |
營業收入 | -54.666 | -54.341 | -59.694 | -41.645 | -44.565 |
利息收入(費用),非經營淨值 | -18.52 | -16.592 | -17.325 | -15.607 | -13.731 |
其他,淨值 | -0.244 | 0.04 | 2.917 | 0.537 | 9.061 |
稅前淨收入 | -73.43 | -70.893 | -74.102 | -56.715 | -49.235 |
稅後淨收入 | -73.43 | -70.893 | -74.102 | -56.715 | -49.235 |
少數股東權益 | 4.414 | 2.639 | 3.009 | 2.493 | 2.801 |
未計算非常項目前的淨收益 | -69.016 | -68.254 | -71.093 | -54.222 | -46.434 |
淨收入 | -69.016 | -68.254 | -71.093 | -54.222 | -46.434 |
Total Adjustments to Net Income | -0.053 | -0.053 | -0.053 | -0.053 | -0.053 |
普通股股東可獲收益 (不含非經常性項目) | -69.069 | -68.307 | -71.146 | -54.275 | -46.487 |
普通股股東可獲收益 (含非經常性項目) | -69.069 | -68.307 | -71.146 | -54.275 | -46.487 |
攤薄淨收入 | -69.069 | -68.307 | -71.146 | -54.275 | -46.487 |
攤薄後加權平均股 | 351.379 | 317.109 | 304.462 | 286.854 | 277.033 |
扣除特別項目的每股攤薄盈利 | -0.19657 | -0.21541 | -0.23368 | -0.18921 | -0.1678 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
每股正常攤薄盈利 | -0.19657 | -0.21541 | -0.22732 | -0.18921 | -0.1678 |
異常費用(收入) | 1.937 | 0 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
流動資産總額 | 213.122 | 331.974 | 113.783 | 86.536 | 74.8077 |
現金和短期投資 | 193.358 | 306.923 | 99.871 | 61.808 | 53.0535 |
現金等價物 | 178.674 | 291.931 | 99.871 | 61.808 | 53.0535 |
短期投資 | 14.684 | 14.992 | |||
應收賬款總額,淨額 | 2.741 | 1.518 | 1.157 | 16.293 | 0.93814 |
應收賬款 - 貿易,淨額 | 2.741 | 1.518 | 1.157 | 16.293 | 0.93814 |
總庫存 | 0 | 0.05549 | |||
預付的費用 | 13.829 | 20.362 | 10.746 | 7.42 | 19.2648 |
其他流動資産,總計 | 3.194 | 3.171 | 2.009 | 1.015 | 1.49572 |
總資産 | 413.556 | 465.958 | 214.514 | 155.335 | 136.401 |
物業/廠房/設備,總計 - 淨額 | 164.286 | 91.083 | 60.27 | 33.69 | 25.1156 |
物業/廠房/設備,總計 - 總額 | 218.361 | 141.622 | 107.471 | 76.551 | 63.1836 |
累計折舊,總計 | -54.075 | -50.539 | -47.201 | -42.861 | -38.068 |
商譽,淨額 | 25.467 | 24.876 | 25.452 | 23.188 | 22.9249 |
無形資産,淨額 | 6.228 | 8.488 | 10.886 | 10.504 | 12.3382 |
其他長期資産,總計 | 4.453 | 9.537 | 4.123 | 1.417 | 1.21439 |
流動負債總額 | 188.952 | 156.943 | 129.884 | 122.209 | 68.0622 |
應付賬款 | 40.939 | 30.486 | 17.015 | 13.564 | 13.6239 |
預提費用 | 40.202 | 44.718 | 31.007 | 32.679 | 24.5513 |
應付票據/短期債務 | 0 | 0 | 0 | 0 | 0 |
長期債務的當前部分/資本租賃 | 8.527 | 1.063 | 1.579 | 0.794 | 0.14606 |
其他流動負債,總計 | 99.284 | 80.676 | 80.283 | 75.172 | 29.7409 |
負債總額 | 474.834 | 431.518 | 391.269 | 353.774 | 268.989 |
長期債務總額 | 24.854 | 13.141 | 18.945 | 13.38 | 13.2115 |
長期債務 | 12.584 | 12.823 | 18.879 | 13.38 | 13.2115 |
其他負債,總計 | 254.652 | 247.965 | 250.266 | 224.166 | 189.794 |
總權益 | -61.278 | 34.44 | -176.755 | -198.439 | -132.588 |
Redeemable Preferred Stock | 0 | 0 | 0 | 32.8321 | |
Preferred Stock - Non Redeemable, Net | 0 | 26.917 | 26.917 | 7.04734 | |
普通股 | 3.056 | 2.569 | 1.961 | 1.378 | 1.19996 |
額外實收資本 | 1644.66 | 1520.21 | 1257.5 | 1059.58 | 1005.18 |
留存收益(累計赤字) | -1709.91 | -1489.83 | -1465.91 | -1284.99 | -1177.31 |
其他權益,總計 | 0.915 | 1.492 | 2.772 | -1.324 | -1.53937 |
總負債和股東權益 | 413.556 | 465.958 | 214.514 | 155.335 | 136.401 |
已發行普通股總數 | 305.573 | 256.898 | 196.091 | 137.818 | 119.996 |
Total Preferred Shares Outstanding | 0.03162 | 0.03162 | 0.04408 | 0.04408 | 0.05008 |
少數股權 | 6.376 | 13.469 | -7.826 | -5.981 | -2.0783 |
資本租賃義務 | 12.27 | 0.318 | 0.066 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
流動資産總額 | 125.55 | 170.735 | 205.689 | 213.122 | 251.432 |
現金和短期投資 | 106.305 | 157.852 | 189.233 | 193.358 | 218.23 |
現金等價物 | 106.305 | 143.205 | 164.819 | 178.674 | 208.354 |
應收賬款總額,淨額 | 1.03 | 1.341 | 1.417 | 2.741 | 8.823 |
應收賬款 - 貿易,淨額 | 1.03 | 1.341 | 1.417 | 2.741 | 8.823 |
預付的費用 | 15.886 | 8.699 | 11.143 | 13.829 | 21.989 |
其他流動資産,總計 | 2.329 | 2.843 | 3.896 | 3.194 | 2.39 |
總資産 | 335.472 | 383.593 | 412.854 | 413.556 | 429.019 |
物業/廠房/設備,總計 - 淨額 | 169.697 | 173.886 | 171.463 | 164.286 | 138.854 |
物業/廠房/設備,總計 - 總額 | 200.429 | 201.847 | 196.553 | 187.092 | 154.188 |
累計折舊,總計 | -60.75 | -58.489 | -56.119 | -54.075 | -53.158 |
商譽,淨額 | 24.666 | 24.728 | 25.623 | 25.467 | 23.936 |
無形資産,淨額 | 4.497 | 4.986 | 5.66 | 6.228 | 6.877 |
其他長期資産,總計 | 11.062 | 9.258 | 4.419 | 4.453 | 7.92 |
流動負債總額 | 198.356 | 204.068 | 190.898 | 188.952 | 173.073 |
應付賬款 | 40.871 | 52.473 | 46.768 | 40.939 | 39.711 |
預提費用 | 40.188 | 32.099 | 35.426 | 40.202 | 30.848 |
應付票據/短期債務 | 0 | 0 | 0 | 0 | 0 |
長期債務的當前部分/資本租賃 | 0.387 | 0.622 | 1.022 | 0.575 | 13.458 |
其他流動負債,總計 | 116.91 | 118.874 | 107.682 | 107.236 | 89.056 |
負債總額 | 464.584 | 476.788 | 471.39 | 474.834 | 449.404 |
長期債務總額 | 12.72 | 12.673 | 12.627 | 12.584 | 0 |
長期債務 | 12.72 | 12.673 | 12.627 | 12.584 | 0 |
少數股權 | 13.82 | 16.434 | 5.427 | 6.376 | 8.549 |
其他負債,總計 | 239.688 | 243.613 | 262.438 | 266.922 | 267.782 |
總權益 | -129.112 | -93.195 | -58.536 | -61.278 | -20.385 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Preferred Stock - Non Redeemable, Net | |||||
普通股 | 3.814 | 3.675 | 3.417 | 3.056 | 2.949 |
額外實收資本 | 1777.48 | 1751.02 | 1715.29 | 1644.66 | 1614.84 |
留存收益(累計赤字) | -1909.38 | -1847.18 | -1778.16 | -1709.91 | -1638.81 |
其他權益,總計 | -1.028 | -0.717 | 0.917 | 0.915 | 0.644 |
總負債和股東權益 | 335.472 | 383.593 | 412.854 | 413.556 | 429.019 |
已發行普通股總數 | 381.382 | 367.491 | 341.663 | 305.573 | 294.948 |
Total Preferred Shares Outstanding | 0.03162 | 0.03162 | 0.03162 | 0.03162 | 0.03162 |
短期投資 | 0 | 14.647 | 24.414 | 14.684 | 9.876 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
净收入/起跑线 | -230.656 | -28.724 | -182.891 | -111.56 | -162.044 |
经营活动产生的现金 | -175.373 | 10.145 | -139.096 | -18.682 | -131.095 |
经营活动产生的现金 | 6.946 | 6.788 | 7.179 | 6.662 | 6.288 |
Deferred Taxes | |||||
非现金物品 | 24.253 | 41.824 | 27.662 | 27.532 | 24.4914 |
已付现金利息 | 1.143 | 1.152 | 1.176 | 1.224 | 1.17109 |
营运资金的变化 | 24.084 | -9.743 | 8.954 | 58.684 | 0.17005 |
投资活动产生的现金 | -33.61 | -43.15 | -4.441 | -4.657 | -3.59092 |
资本支出 | -53.062 | -33.814 | -3.466 | -4.657 | -3.59711 |
其他投资现金流量项目,总计 | 19.452 | -9.336 | -0.975 | 0 | 0.00619 |
融资活动产生的现金 | 95.83 | 225.264 | 183.855 | 31.323 | 128.285 |
融资现金流项目 | 0 | -1.542 | 0 | 204.384 | |
股票的发行(报废),净额 | 96.32 | 228.123 | 180.89 | 31.643 | 86.0315 |
债务的发行(退还),净额 | -0.49 | -1.317 | 2.965 | -0.32 | -162.131 |
外汇效应 | -0.104 | -0.164 | 0.379 | 0.77 | -0.73257 |
现金净变化 | -113.257 | 192.095 | 40.697 | 8.754 | -7.13309 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -70.893 | -230.656 | -156.554 | -99.839 | -50.604 |
Cash From Operating Activities | -58.526 | -175.373 | -128.035 | -95.844 | -52.391 |
Cash From Operating Activities | 2.562 | 6.946 | 5.057 | 3.35 | 1.66 |
Non-Cash Items | 3.267 | 24.253 | 21.364 | 10.1 | 1.775 |
Cash Interest Paid | 0.83 | 1.143 | 0.847 | 0.568 | 0.279 |
Changes in Working Capital | 6.538 | 24.084 | 2.098 | -9.455 | -5.222 |
Cash From Investing Activities | -11.489 | -33.61 | -27.227 | -11.591 | -7.533 |
Capital Expenditures | -1.842 | -53.062 | -38.716 | -22.996 | -4.544 |
Cash From Financing Activities | 56.25 | 95.83 | 72.057 | 43.834 | 16.038 |
Issuance (Retirement) of Stock, Net | 58.138 | 96.32 | 72.305 | 44.012 | 16.17 |
Issuance (Retirement) of Debt, Net | -1.888 | -0.49 | -0.248 | -0.178 | -0.132 |
Foreign Exchange Effects | -0.09 | -0.104 | -0.372 | 0.055 | -0.336 |
Net Change in Cash | -13.855 | -113.257 | -83.577 | -63.546 | -44.222 |
Other Investing Cash Flow Items, Total | -9.647 | 19.452 | 11.489 | 11.405 | -2.989 |
Financing Cash Flow Items | 0 | 0 |
差價合約交易計算器
如果您在特定日期(選取一個日期)開立差價合約交易並在不同日期(選取一個日期)關閉交易,計算您的假設盈虧。
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Agenus Company profile
关于 Agenus Inc
Agenus Inc.是一家处于临床阶段的免疫肿瘤学(I-O)公司。 它有一个免疫检查点抗体、采用细胞疗法和新抗原癌症疫苗的管道,以对抗癌症。 其I-O资产包括基于抗体的治疗方法、单特异性和双特异性抗体、细胞疗法、疫苗和佐剂。 其候选抗体是Balstilimab(一种抗PD-1抗体)和Zalifrelimab(一种抗CTLA-4抗体),作为单药(balstilimab)和联合疗法(balstilimab/zalifrelimab)治疗二线宫颈癌患者,目前处于第二阶段试验。 其临床阶段的资产组合还包括Botensilimab(AGEN1181)、AGEN2373、AGEN1423、AGEN1777、MK-4830、INCAGN2390、INCAGN2385和AGENT797。 该公司正在开发个性化疫苗,即Prophage和AutoSynVax,以及现成的疫苗PhosphoSynVax,其中包含热休克蛋白,将新抗原传递给合适的免疫细胞以激活抗癌免疫反应。
Industry: | Biotechnology & Medical Research (NEC) |
3 Forbes Rd
LEXINGTON
MASSACHUSETTS 02421-7305
US
收入報表
- Annual
- Quarterly
人們也觀看
还在找一位您可以信任的经纪商吗?
加入成为全球580,000万多名交易者的一份子,选择利用Capital.com进行交易吧。